CHMP recommends EU approval of Roche's Polivy combination for people with previously untreated diffuse large B-cell lymphoma

Polivy plus R-CHP showed first clinically meaningful improvement in PFS with comparable safety in people with previously untreated diffuse large B-cell lymphoma over the standard of care in... | March 25, 2022

Related Keywords

Portugal ,Japan ,Lugano ,Ticino ,Switzerland ,United States ,France ,Belgium ,America ,Polatuzumab Vedotin ,Nathalie Meetz ,Sileia Urech ,Levi Garraway ,Loren Kalm ,Karsten Kleine ,Genentech ,European Commission ,World Health Organization ,Head Of Global Product Development ,Lymphoma Study Association ,Roche Group ,Roche Group Media Relations ,Lymphoma Academic Research Organisation ,European Medicines Agency ,Medicinal Products ,Human Use ,Chief Medical Officer ,Global Product ,England Journal ,Lugano Response Criteria ,Dow Jones Sustainability Indices ,Chugai Pharmaceutical ,Cancer Incidence ,Previously Untreated Diffuse Largeb Cell ,Roche Holding Ag Stock Exchange ,News ,Information ,Press Release ,Polivy ,Plus ,Howed ,First ,Linically ,Meaningful ,Improvement ,N ,Ifs ,Ith ,Comparable ,Safety ,People ,Reviously ,Untreated ,Diffuse ,Barge ,Lymphoma ,Dover ,The ,Standard ,F ,Are Rog Ch0012032048 ,